/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration.
Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders bought 5,840 call options on the stock. This represents an increase of approximately 934% compared to the average daily volume of 565 call options. Insiders Place Their Bets In other news, EVP William P. Forbes […]
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO, Jan. 7, 2024 /PRNewswire/ Heron Therapeutics, Inc. , a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Up 22.7% in November theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.